{"DataElement":{"publicId":"2597188","version":"1","preferredName":"Agent Oral Administration Type","preferredDefinition":"the type or agent orally administered.","longName":"AGT_ORAL_ADMIN_TP","context":"NIDCR","contextVersion":"1","DataElementConcept":{"publicId":"2594236","version":"1","preferredName":"Agent Oral Administration","preferredDefinition":"information related to dispensing, applying, or administration of a medicine by mouth.","longName":"AGT_ADMIN","context":"NIDCR","contextVersion":"1","ObjectClass":{"publicId":"2321156","version":"1","preferredName":"Agent","preferredDefinition":"A natural, synthetic or semisynthetic substance that has specific characteristics. (NCI)","longName":"CL111054","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Agent","conceptCode":"CL111054","definition":"A natural, synthetic or semisynthetic substance that has specific characteristics. (NCI)","evsSource":"NCI_META_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC71B93E-0593-5AD9-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-26","modifiedBy":"ONEDATA","dateModified":"2005-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2594234","version":"1","preferredName":"Oral Administration","preferredDefinition":"Oral; of, or relating to, or affecting, or for use in the mouth.:The act of administration.","longName":"C25311:C25409","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oral","conceptCode":"C25311","definition":"Of, or relating to, or affecting, or for use in the mouth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Administration","conceptCode":"C25409","definition":"The act of the dispensing, applying, or tendering of something to another, such as administration of a medicine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28FCE688-66B2-2452-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-08","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-02-08","modifiedBy":"ONEDATA","dateModified":"2007-02-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28FCE6CB-D41C-246C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-08","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-02-08","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2597177","version":"1","preferredName":"Agent Oral Administration Type","preferredDefinition":"the type of orally administered agent.","longName":"AGT_ORAL_ADMIN_TP","context":"NIDCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Actonel or Risedronate","valueDescription":"Risedronate Sodium","ValueMeaning":{"publicId":"2597179","version":"1","preferredName":"Risedronate Sodium","longName":"2597179","preferredDefinition":"(ris-ED-roe-nate) A substance that is being studied in the prevention and treatment of osteoporosis. It belongs to the family of drugs called bone resorption inhibitors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Risedronate Sodium","conceptCode":"C1528","definition":"The sodium salt of risedronic acid, a synthetic pyridinyl bisphosphonate. Risedronic acid binds to hydroxyapatite crystals in bone and inhibits osteoclast-dependent bone resorption.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2972C10F-0F67-54BE-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-14","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-02-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2972C10F-0F7F-54BE-E044-0003BA3F9857","beginDate":"2007-02-14","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-02-14","modifiedBy":"ALAIS","dateModified":"2007-02-14","deletedIndicator":"No"},{"value":"Boniva or Ibandronate","valueDescription":"Ibandronate Sodium","ValueMeaning":{"publicId":"2597181","version":"1","preferredName":"Ibandronate Sodium","longName":"2597181","preferredDefinition":"The sodium salt form of ibandronate, a synthetic nitrogen-containing bisphosphonate.  Ibandronate inhibits farnesyl pyrophosphate synthase, resulting in a reduction in geranylgeranyl GTPase signaling proteins and apoptosis of osteoclasts. This agent increases bone mineral density, decreases bone remodeling, inhibits osteoclast-mediated bone resorption, and reduces metastases-related and corticosteroid-related bone pain. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ibandronate Sodium","conceptCode":"C1670","definition":"The sodium salt form of ibandronic acid, a synthetic nitrogen-containing bisphosphonate. Ibandronic acid inhibits farnesyl pyrophosphate synthase, resulting in a reduction in geranylgeranyl GTPase signaling proteins and apoptosis of osteoclasts. This agent increases bone mineral density, decreases bone remodeling, inhibits osteoclast-mediated bone resorption, and reduces metastases-related and corticosteroid-related bone pain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2972C181-8505-54D4-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-14","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-02-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2972C181-851D-54D4-E044-0003BA3F9857","beginDate":"2007-02-14","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-02-14","modifiedBy":"ALAIS","dateModified":"2007-02-14","deletedIndicator":"No"},{"value":"Didronel or Etidronate","valueDescription":"Etidronate Disodium","ValueMeaning":{"publicId":"2597183","version":"1","preferredName":"Etidronate Disodium","longName":"2597183","preferredDefinition":"A synthetic therapeutic diphosphonate analogue of endogenous pyrophosphate. As a member of the family of drugs known as bisphosphonates, etidronate disodium differs from endogenous pyrophosphate in its resistance to enzymatic hydrolysis.  This agent adsorbs to hydroxyapatite cells and reduces the number of osteoclasts, thereby inhibiting abnormal bone resorption.  Etidronate may also directly stimulate bone formation by osteoblasts. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Etidronate Disodium","conceptCode":"C831","definition":"A synthetic therapeutic diphosphonate analogue of endogenous pyrophosphate. As a member of the family of drugs known as bisphosphonates, etidronate disodium differs from endogenous pyrophosphate in its resistance to enzymatic hydrolysis.  This agent adsorbs to hydroxyapatite cells and reduces the number of osteoclasts, thereby inhibiting abnormal bone resorption.  Etidronate may also directly stimulate bone formation by osteoblasts. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2972C1E6-9866-54DE-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-14","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-02-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2972C1E6-987E-54DE-E044-0003BA3F9857","beginDate":"2007-02-14","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-02-14","modifiedBy":"ALAIS","dateModified":"2007-02-14","deletedIndicator":"No"},{"value":"Fosamax or Alendronate","valueDescription":"Alendronate Sodium","ValueMeaning":{"publicId":"2576907","version":"1","preferredName":"Alendronate Sodium","longName":"2576907","preferredDefinition":"A bisphosphonate with increased antiresorption activity (100x-1000x that of etidronate).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alendronate Sodium","conceptCode":"C973","definition":"The sodium salt of alendronate, a second generation bisphosphonate and synthetic analog of pyrophosphate with bone anti-resorption activity. Alendronate sodium binds to and inhibits the activity of geranyltranstransferase (farnesyl pyrophosphate synthetase), an enzyme involved in terpenoid biosynthesis. Inhibition of this enzyme prevents the biosynthesis of isoprenoid lipids (FPP and GGPP) that are donor substrates of farnesylation and geranylgeranylation during the post-translational modification of small GTPase signalling proteins, which is important in the process of osteoclast turnover. As a result, osteoclast activity is inhibited and bone resorption and turnover are reduced.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F978-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-24","modifiedBy":"REEVESD","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2972C1E6-988A-54DE-E044-0003BA3F9857","beginDate":"2007-02-14","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-02-14","modifiedBy":"ALAIS","dateModified":"2007-02-14","deletedIndicator":"No"},{"value":"Skelid or Tiludronate","valueDescription":"Tiludronate Disodium","ValueMeaning":{"publicId":"2597185","version":"1","preferredName":"Tiludronate Disodium","longName":"2597185v1.00","preferredDefinition":"The disodium salt form of tiludronate, a first-generation, non-nitrogenous bisphosphonate analogue of endogenous pyrophosphate. Tiludronate adsorbs to hydroxyapatite cells, and although the exact mechanism through which this bisphosphonate exerts its effect has yet to be fully elucidated, tiludronate appears to inhibit protein-tyrosine-phosphatase (PTP) in osteoclasts, thereby disrupting the cytoskeletal ring structure and suppressing the bone resorbing activity of osteoclasts. In addition, tiludronate appears to inhibit the vacuolar-type proton ATPase (V-ATPase) in osteoclasts. Altogether, this may reduce the number of osteoclasts, inhibit abnormal bone resorption and reduce bone turnover.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tiludronate Disodium","conceptCode":"C61973","definition":"The disodium salt form of tiludronate, a first-generation, non-nitrogenous bisphosphonate analogue of endogenous pyrophosphate. Tiludronate adsorbs to hydroxyapatite cells, and although the exact mechanism through which this bisphosphonate exerts its effect has yet to be fully elucidated, tiludronate appears to inhibit protein-tyrosine-phosphatase (PTP) in osteoclasts, thereby disrupting the cytoskeletal ring structure and suppressing the bone resorbing activity of osteoclasts. In addition, tiludronate appears to inhibit the vacuolar-type proton ATPase (V-ATPase) in osteoclasts. Altogether, this may reduce the number of osteoclasts, inhibit abnormal bone resorption and reduce bone turnover.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2972C254-D56A-54E8-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-14","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-02-14","modifiedBy":"KUMMEROA","dateModified":"2023-08-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2972C254-D582-54E8-E044-0003BA3F9857","beginDate":"2007-02-14","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-02-14","modifiedBy":"ALAIS","dateModified":"2007-02-14","deletedIndicator":"No"},{"value":"Actonel and Calcium or Risedrone + Calcium Carbonate","valueDescription":"Actonel and Calcium or Risedrone + Calcium Carbonate","ValueMeaning":{"publicId":"2597189","version":"1","preferredName":"Actonel and Calcium or Risedrone + Calcium Carbonate","longName":"2597189","preferredDefinition":"Actonel and Calcium or Risedrone + Calcium Carbonate","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2972D454-090E-5770-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-14","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-02-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2972D9F8-4AEC-5795-E044-0003BA3F9857","beginDate":"2007-02-14","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-02-14","modifiedBy":"ONEDATA","dateModified":"2007-02-14","deletedIndicator":"No"},{"value":"Fosamax Plus D or Alendronate + Vitamin D","valueDescription":"Fosamax Plus D or Alendronate + Vitamin D","ValueMeaning":{"publicId":"2597190","version":"1","preferredName":"Fosamax Plus D or Alendronate + Vitamin D","longName":"2597190","preferredDefinition":"Fosamax Plus D or Alendronate + Vitamin D","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2972D767-8EA6-54DC-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-14","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-02-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2972D9F8-4AFE-5795-E044-0003BA3F9857","beginDate":"2007-02-14","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-02-14","modifiedBy":"ONEDATA","dateModified":"2007-02-14","deletedIndicator":"No"},{"value":"An oral bisphosphonate of which you don't remember the name","valueDescription":"An oral bisphosphonate of which you don't remember the name","ValueMeaning":{"publicId":"2597191","version":"1","preferredName":"An oral bisphosphonate of which you don't remember the name","longName":"2597191","preferredDefinition":"An oral bisphosphonate of which you don't remember the name","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2972D98C-A67F-42AF-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-14","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-02-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2972D9F8-4B10-5795-E044-0003BA3F9857","beginDate":"2007-02-14","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-02-14","modifiedBy":"ONEDATA","dateModified":"2007-02-14","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2972C102-C87C-526A-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-14","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-02-14","modifiedBy":"SBR","dateModified":"2008-12-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2857180","version":"1","longName":"Type of Category","context":"NIDCR","ClassificationSchemeItems":[{"publicId":"2812084","version":"1","longName":"Diagnostic","context":"NIDCR"},{"publicId":"2812085","version":"1","longName":"Preventive","context":"NIDCR"}]},{"publicId":"2857182","version":"1","longName":"Protocol Forms","context":"NIDCR","ClassificationSchemeItems":[{"publicId":"2812041","version":"1","longName":"NIDCR","context":"NIDCR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Have you EVER taken any of th","type":"Preferred Question Text","description":"Have you EVER taken any of the following drugs orally or BY MOUTH","url":null,"context":"NIDCR"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"2972CAB8-CF00-563A-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-14","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-02-14","modifiedBy":"ALAIS","dateModified":"2011-08-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}